Clinical Trial Update: A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study [Phase 2]

View source ↗

Summary

BRACELET-1 is a Phase 2 study evaluating the combination of Pelareorep with Avelumab and paclitaxel in metastatic breast cancer to assess overall response rate;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Avelumab (avelumab)
• PACLITAXEL (PACLITAXEL)
• Pelareorep (pelareorep)

Snippet

Sponsor: Oncolytics Biotech | Conditions: Breast Cancer Metastatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-16